Fenistil drops 1 mg/ml. 20 ml. vial


Manufacturer: Switzerland

Symptomatic treatment of allergic diseases: urticaria, seasonal (hay fever) and year-round allergic rhinitis, allergies to medicines and food. Itching of various origins, except for those associated with cholestasis. Itching in diseases with skin rashes, such as chickenpox. An adjuvant for eczema and other itchy dermatoses of allergic origin. Skin itching, such as insect bites, neobirna solar erythema, uncomplicated small skin burns and allergic irritation of small areas of skin.



Fenistil drops Composition
active substance: dimethindene maleate;

1 ml contains 1 mg of dimethindene maleate;

Fenistil drops excipients: sodium phosphate, dodecahydrate; propylene glycol; benzoic acid E 210; Trilon B; citric acid, monohydrate, sodium saccharin, purified water.

Fenistil drops Dosage form
Oral drops.

Basic physical and chemical properties: transparent solution, colorless or slightly brownish-yellow.

Pharmacotherapeutic group
Antihistamines for systemic use. ATX code R06A B03.

Dimethindene maleate is a histamine antagonist at the H1 receptor level. In low concentrations, it has a stimulating effect on histamine methyltransferase, which leads to inactivation of histamine. It has a high affinity for H1 receptors and is a mast cell stabilizer. Maleate does not affect the H2 receptors of dimethindene. It also has local anesthetic properties.

Dimethindene maleate is an antagonist of bradykinin, serotonin and acetylcholine. It exists in the form of a racemic mixture with R – (-) – Dimethindene, which has a more pronounced H1-antihistamine activity.

Dimetindene maleate significantly reduces capillary hyperpermeability associated with immediate hypersensitivity reactions.

In combination with H2-receptor antagonists, it inhibits almost all types of histamine action on the circulatory system.

Studies have shown that the effect of a single dose of 4 mg of dimetindene in the form of drops on skin reactions is determined up to 24 hours after administration of the drug.

The systemic bioavailability of dimethindene in the form of drops is approximately 70%. After taking the drops, the maximum concentration of dimetindene in the blood plasma is reached within 2 hours.

At concentrations from 0.09 to 2 μg / ml, the binding of dimethindene to blood plasma proteins is approximately 90%. Metabolic reactions of dimethindene include hydroxylation and methoxylation.

The half-life of dimetindene is almost 6 hours. Dimethindene and its metabolites are excreted by the liver and kidneys.

When conducting preclinical studies, no risk was identified when using the drug in recommended doses. Dimetindene maleate showed no mutagenic or clastogenic properties.


Symptomatic treatment of allergic diseases: urticaria, seasonal (hay fever) and perennial allergic rhinitis, drug and food allergies.
Itching of various origins, except associated with cholestasis. Itching in conditions with skin eruptions such as chickenpox. Insect bites.
Adjuvant for eczema and other itchy dermatoses of allergic genesis.


Hypersensitivity to dimethindene maleate or to any other component of the drug. Duodenal / pyloric stenosis.
Contraindicated in children under 1 month of age, especially premature babies.